# Inhibrx (INBX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/INBX
## Company Profile
- Ticker: INBX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 121.17 USD
- Market cap: 1373663145.1799998 USD
- Last updated: 2026-09-04
## Business Overview
### Protein-Engineering Company
Inhibrx Biosciences develops multivalent biologics using protein-engineering platforms designed around the specific signaling requirements of complex therapeutic targets.
### Ozekibart
Ozekibart, formerly INBRX-109, is a tetravalent DR5 agonist under FDA review for conventional chondrosarcoma. Additional development combines the candidate with standard regimens in colorectal cancer.
### INBRX-106
INBRX-106 is a multivalent OX40 agonist intended to enhance antitumor immune activation. A randomized Phase 2 study combines it with pembrolizumab in head-and-neck squamous-cell carcinoma.
### Dual Oncology Franchise
The company's near-term strategy combines a registration-stage rare-cancer program with broader combination development in colorectal and head-and-neck cancers.
## Why The Stock Is Moving

The latest monitored company update is “Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Progression-free-survival data from the randomized Phase 2 INBRX-106 study in the third quarter of 2026.
- FDA meeting on ozekibart development in colorectal cancer in the fourth quarter of 2026.
- Interim data from the ozekibart colorectal-cancer cohorts in the first quarter of 2027.
- FDA action on the ozekibart BLA by the April 14, 2027 PDUFA goal date.

## Drug Assets

- INBRX-106

## Recent News
- 2026-09-04 20:00 EST — [Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study](https://biopharmsignal.com/news/INBX/inhibrx-to-host-webcast-presentation-to-provide-primary-endpoint-results-for-inb-14d23ad0) — Source: Inhibrx
- 2026-08-13 20:04 EST — [Inhibrx Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/INBX/inhibrx-reports-second-quarter-2026-financial-results-46b64780) — Source: Inhibrx
- 2026-07-16 13:00 EST — [Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million](https://biopharmsignal.com/news/INBX/inhibrx-announces-amended-loan-agreement-with-oxford-finance-expanding-total-fac-d29cd85b) — Source: Inhibrx
- 2026-06-15 13:15 EST — [Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma](https://biopharmsignal.com/news/INBX/inhibrx-announces-u-s-fda-acceptance-of-bla-for-ozekibart-in-patients-with-conve-d0380d86) — Source: Inhibrx
- 2026-05-14 20:02 EST — [Inhibrx Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/INBX/inhibrx-reports-first-quarter-2026-financial-results) — Source: Inhibrx